美国胸科医师学会评分评估静脉血栓栓塞患者抗凝期间出血风险
在意大利START2注册的2263例长期抗凝的静脉血栓栓塞患者中评估ACCP出血风险评分。超过半数被归为高风险,但长期抗凝期间出血率较低(1.53%/年)。ACCP评分的c统计量为0.55、0.50和0.56(低、中、高风险组),预测价值不足,不能用于指导延长抗凝决策。
要点
- 超过半数患者被ACCP评分归为高风险,但高风险组长期抗凝超过1年的比例反而高于低风险组。
- 队列总体出血发生率为1.53%/年,高风险组1.7%/年,低风险组0.95%/年。
- 治疗前90天出血发生率(3.0%/年)高于之后(1.2%/年),RR为2.5(1.3-4.7)。
核心结论
- ACCP评分对长期抗凝患者的出血预测价值不足(c统计量0.50-0.56),不能用于指导延长抗凝决策。
- 需要新的预测工具来评估包括DOACs在内的抗凝治疗期间的出血风险。
研究设计与样本
- 基于意大利START2注册的起始队列研究,纳入2263例长期抗凝的静脉血栓栓塞患者,其中1522例使用维生素K拮抗剂(VKA),其余使用直接口服抗凝药(DOAC)。
主要发现
- 超过半数患者被ACCP评分归为高风险,但高风险组接受抗凝超过1年的比例高于低风险组。
- 中位随访12个月(四分位距6-24个月),共3130患者年,发生48例出血结局,总体出血率1.53%/年;高风险组1.7%/年,低风险组0.95%/年。
- ACCP评分的c统计量在低、中、高风险组分别为0.55(0.48-0.63)、0.50(0.42-0.58)和0.56(0.48-0.64)。
- 治疗前90天出血发生率3.0%/年,之后1.2%/年,相对风险(RR)2.5(1.3-4.7);三个风险类别间出血发生率相似。
- 初始3个月VKA组与DOAC组出血率无差异;后续期间DOAC组出血率低于VKA组(0.5%/年 vs 1.4%/年)。
关键数值与推荐
- ACCP评分将超过半数患者归为高风险,但该评分对出血的预测c统计量仅为0.50-0.56。
- 总体出血率1.53%/年,高风险组1.7%/年,低风险组0.95%/年。
- 前90天出血率3.0%/年 vs 之后1.2%/年,RR 2.5(1.3-4.7)。
- 后续期间DOAC组出血率0.5%/年 vs VKA组1.4%/年。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: Essentials The risk of bleeding influences the duration of anticoagulation (AC) after venous thromboembolism. We assessed the ACCP bleeding risk score in an inception-cohort of patients receiving AC. 53% were categorized at high-risk, but their bleeding rate was low during long-term AC. ACCP score had low predictive value for bleeding. SUMMARY: Background The American College of Chest Physicians (ACCP) guideline proposes a score to decide on extended anticoagulation after an unprovoked venous thromboembolism (VTE). Methods We investigated the ACCP score to predict bleeding risk in an inception cohort of 2263 patients on long-term anticoagulation (1522 treated with vitamin K antagonists [VKAs] and the remaining with direct oral anticoagulants [DOACs]) belonging to the Italian START2 Register. Results More than half the patients were categorized as high risk; nevertheless, a higher proportion received anticoagulation for > 1 year compared with those in the low-risk category. For 3130 years (median 12 [interquartile range 6, 24] months), 48 bleeding outcomes occurred (1.53%/year) in the cohort (1.7%/year and 0.95%/year in high- and low-risk categories, respectively). The c-statistic of the ACCP score was 0.55 (0.48-0.63), 0.50 (0.42-0.58) and 0.56 (0.48-0.64) in low-, moderate- and high-risk categories, respectively. The bleeding incidence was higher during the first 90 days of treatment (3.0%/year) than afterwards (1.2%/year; relative risk (RR), 2.5 [1.3-4.7]), and similar among the three categories. The bleeding rate was not different during the initial 3 months of treatment in patients receiving VKAs or DOACs; it was, however, lower in the latter patients in the subsequent period (0.5%/year vs. 1.4%/year, respectively). Conclusion The bleeding rate during extended treatment was rather low in our patients. ACCP score had insufficiently predictive value for bleeding and cannot be used to guide decisions on extended treatment. New prediction tools for bleeding risk during anticoagulant treatments (including DOACs) are required.
引用
- Palareti G, Antonucci E, Mastroiacovo D, et al. The American College of Chest Physician score to assess the risk of bleeding during anticoagulation in patients with venous thromboembolism. J Thromb Haemost. 2018. PMID: 30059189. doi:10.1111/jth.14253
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。